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variables. Cox proportional harzards model was used to identify
risk factors for survival. Analyzed risk factors were: age, sex, diag-
nosis, disease stage, acute GVHD (grade II-IV), extensive
c-GVHD, stem cell source (cord blood x bone marrow), use of
antibodies directed to T-cells and HLA matching. Diagnosis were:
CML-46; AML/MDS-40, ALL-34, OTHERS-5. Male: 78; fe-
male: 44; median age 17 years (range: 1-55). Cell source was bone
marrow in 95 patients, cord blood in 30 patients. Conditioning
regimen was nomyeloablative in 8 patients and conventional in 114
patients. 25 patients received ATG or ALG as part of their con-
ditioning regimen and 90 patients received cyclophosphamide and
TBI. Sixty-six patients (53%) had advanced disease at the time of
transplant (CML advanced phase, AML or ALL in  second
remission, relapsed or refractory).
RESULTS: Acute GVHD grade II-IV was observed in 51 pa-
tients (41%) and was the primary cause of death in 9% of the
patients. Extensive chronic GVHD was observed in 32 patients
(26%) and was the primary cause of death in 13% of the patients.
Other causes of death included: infection in 32 (41%) and relapse
in 21 (27%) of the patients. Estimated 10 years overall survival was
40% with a median survival of 189 days. There was no difference
in survival according sex, diagnosis, stem cell source, type of con-
ditioning, number of cells infused or HLA compatibility. There
was a signiﬁcant better 10 years survival for early disease, compared
to advanced disease (55% x 20%; p0.0005), age less than 18 x
more than 18 (60% x 20%; p0.0012). Extensive c-GVHD was
protective for overall survival (P0.0340; Odds ratio 0.3998;
95% CI0.1758 to 0.9092).
CONCLUSIONS: 1) Estimated 10 y overall survival was 55%
for patients with early disease; 2) Extensive c-GVHD had a pro-
tective effect on OS, probably due to graft versus malignant effect.
3) Age less than 18 years and early disease were favorable risk
factors for survival.
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PLATEAU IN THE DISEASE-FREE SURVIVAL CURVE AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA MAY SIGNIFY CURE: A LONG-TERM SINGLE INSTITUTION
EXPERIENCE
Ganguly, S.1, Divine, C.L.1, Deauna-Limayo, D.1,
Bodensteiner, D.C.1, Lewis, J.L.1, Hoffmann, T.1, Curran, K.1,
Skikne, B.S.1 1University of Kansas Medical Center, Kansas City, KS.
Introduction: Allogeneic Stem Cell Transplantation (AlloSCT)
through the graft-versus-leukemia (GVL) effect holds the promise
of a long-term cure in patients with acute myeloid leukemia
(AML).
Methods: In an attempt to examine whether AlloSCT provides
long-term disease control in patients with AML, we retrospectively
evaluated our experience and analyzed the outcomes of ASCT in
patients with AML from 1978 to 2005.
Results: Fifty-nine males and 46 females (n105) of median age
32 years (range: 5-60 years) were treated. Of these, 65 were in CR
at the time of transplantation, 40 patients were transplanted with
active disease. Fifty patients were transplanted in ﬁrst remission.
Bone marrow was used in 75 patients as the source of stem cells
prior to 1995 and peripheral blood stem cells (PBSC) were used in
30 patients. Ninety-four of 105 patients engrafted (90%). Median
time for neutrophil recovery was 16 days (range: 9-90 days) and 23
days (range: 9-106 days) for platelets. Median duration of fol-
low-up for those who did not succumb to early transplant-related
mortality (100 days) was 2 years (range: 102 days-21 years).
Median survival time of this cohort was 2 years. Of the 105
patients, 77 have died. Thirty-four patients (32%) died within
100-days of transplantation. Overall survival (OS) of all patients
who did not succumb to TRM was 47% at 5-years, 38% at
10-years and 15-years respectively. No relapse occurred after 4.25
years. OS in patients transplanted in CR (n65) at 5-years was
72%, and at 10 and 15-years was 62% respectively. For those
transplanted with disease (n40), a complete response was
achieved in 23 patients (22%), with a median survival of 214 days.
Disease status at transplantation was a signiﬁcant variable for
survival (p0.01). Most frequent cause of death was infection (27
out of 105 patients). Five patients developed late onset myelodys-
plastic syndrome/secondary malignancy. Patients with any graft-
versus-host-disease (GVHD) had better survival compared to pa-
tients with no GVHD, underscoring the role of GVL effect in
long-term disease control.
Conclusion: In conclusion, AlloSCT provides a possible cure in
a proportion of patients with AML as evidenced by a plateau in the
DFS curve after 4.25 years.
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REDUCED-INTENSITY STEM CELL TRANSPLANTATION IN PATIENTS
WITH HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Gutierrez-Aguirre, C.H.1, Ruiz-Argu¨elles, G.J.2, Cantu-Rodriguez, O.G.1,
Gonzalez-LLano, O.1, Gomez-Almaguer, D.1 1Servicio de Hematologia del
Hospital Universitario de la U.A.N.L., Monterrey, Nuevo Leon, Mexico;
2Centro de Hematologia y Medicina Interna de Puebla, Puebla, Mexico.
Introduction: Despite the optimal use of the antileukemic
agents, reported cure rates no exceed 40% in high-risk ALL adult
patients. The use of hematopoietic stem cell transplantation
(HSCT) is other option in these patients and non-myeloablative
conditioning is a friendly alternative to the conventional and more
toxic myeloablative radio-chemtotherapy scheme, but there is very
limited information using this kind of transplantation in ALL. We
prospectively evaluated the therapeutic value of non-myeloablative
conditioning HSCT in 43 high risk ALL patients in second or
subsequent remission. Patients and methods. Forty three ALL
high-risk patients were prospectively allografted, using HLA-iden-
tical siblings as donors. Patients received oral busulphan 4 mg /
Kg/2 days, i.v. cyclophosphamide 350 mg /m2/3 days and i.v.
ﬂudarabine 30 mg /m2/3 days; oral cyclosporin A 4 mg / Kg was
started on day - 1 and i.v. methotrexate 5 mg / m2 was delivered on
days  1,  3,  5 and  11. Median age of the patients was 19
years; there were 19 females. Patients received a median of 5.0 
106/ Kg CD34 cells. Results: Median time to achieve above 0.5 
109/L granulocytes was 14 days, whereas median time to achieve
above 20  109/L platelets was 15 days. Thirteen patients (30%)
are alive 491 days (median) after the HSCT. The 861-day proba-
bility of survival is 22%, whereas median survival is 200 days. Ten
patients (23%) developed acute graft versus-host disease (GVHD),
and 8 patients (18.6%) developed chronic GVHD. Twenty eight
(65%) patients showed relapse, in 9 cases despite the GVHD.
Thirty patients died between day 47 and 1050 after the HSCT,
most of them (70%) of an ALL relapse. The 100-day mortality was
25.5 %. Conclusion: Relapse remains the ﬁrst cause of death in
high-risk ALL patients. Non-myeloablative HCST seems to have
limited therapeutic effect in ALL patients with advanced disease.
New ideas and emerging strategies should be employed in order to
improve the outcome of these patients, like enhancement of graft-
versus leukemia effects and the use HSCT in ﬁrst complete remis-
sion.
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NEUROLOGICAL COMPLICATIONS IN THE RECIPIENTS OF ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANT
Siegal, D.1, Keller, A.2, Xu, W.3, Bhuta, S.2, Loach, D.1, Kim, D.1,
Walia, J.1, Kuruvilla, J.1, Lipton, J.1, Minden, M.1, Messner, H.1,
Gupta, V.1 1Blood and Marrow Transplant Program, Princess Margaret
Hospital, Toronto, ON, Canada; 2Department of Radiology, University
Health Network, Toronto; 3Department of Biostatistics, Princess Mar-
garet Hospital, Toronto.
The prevalence of neurological complications in allogeneic he-
matopoietic cell transplant (AlloHCT) recipients, the mechanisms
of its development, and its impact on outcome are not well deﬁned.
We reviewed the medical records of 302 consecutive patients, who
underwent AlloHCT for hematologic diseases at Princess Marga-
ret Hospital between January 2002 and November 2005. Patient,
disease and transplant related factors were systematically analyzed.
Stem cells were obtained via peripheral blood (n213) and bone
marrow (n89) from HLA-matched siblings/other family
(n224), HLA-matched unrelated donors (n52) and HLA-mis-
matched donors (n26). Median age of the recipients was 45 years
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(range 18-71) and 59% were males. Intensity of conditioning
regimens was: conventional, 243 (80%); reduced/minimal, 59
(20%). Prior to BMT, 40 patients had received Imatinib and 21
(7%) had a signiﬁcant neurological history: CNS involvement by
primary disease, 12; history of CVA/TIA, 4; seizures, 5.
The cumulative incidence of neurological complications at 30,
100, 180 and 365 days was 9%, 18%, 20% and 23%, respectively.
Manifestations of neurological complications within 100 days
(n53) of transplant were seizures (n19), visual disturbances
(n9), altered level of consciousness (n7), confusion/delirium
(n11) and others (n7). For the patients surviving 100 days
(n255), 17 developed neurological complications manifesting as
seizures (n3), altered level of consciousness (n1), visual distur-
bance (n4), confusion/delirium (n7) and others (n2). Of the
22 patients with seizures, the etiology was posterior reversible
encephalopathy syndrome (PRES) in 15 (68%). Of the 21 patients
with signiﬁcant neurological history prior to BMT, 4 developed
seizures.
Multivariate regression analysis identiﬁed female gender and
high-dose total-body irradiation (TBI) containing conditioning
regimens as the independent risk factors for neurological compli-
cations in ﬁrst 100 days of transplant (Table 1).
Survival at 1-year was signiﬁcantly inferior in patients who de-
veloped neurological complications in ﬁrst 100 days of transplant
compared to those who did not (27% versus 71%, p0.0001).
We conclude that neurological complications in ﬁrst 100 days
have a signiﬁcantly adverse impact on survival in the recipients of
AlloHCT. High-dose TBI containing conditioning regimens
should be avoided in the patients considered at a higher risk for
neurological complications.
Table 1. Multivariate Regression analysis for risk factors for
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MIXED CHIMERISM (MC) AFTER STANDARD ALLO STEM CELL TRANS-
PLANTATION (SCT) IN CHILDREN: 1) CAN MC BE USED AS A PREDIC-
TOR OF RELAPSE? 2) WHEN DOES MC BECOME STABLE AFTER TRANS-
PLANT OF NON-MALIGNANT PATIENTS?
Heilmann, C.1, Madsen, H.O.2, Muller, K.G.1, Jacobsen, N.1 1Bone
Marrow Transplant Unit, Rigshospitalet, University Hospital, Copen-
hagen, Denmark; 2Tissue Typing Laboratory, Rigshospitalet, University
Hospital, Copenhagen, Denmark.
The purpose of this investigation was to evaluate: 1) Whether the
presence of MC early in the post SCT course is a risk factor for
later relapse. 2) To examine in non-malignant diseases when MC
becomes stable after SCT.
Patients and methods: MC was determined by PCR based ana-
lyzes of microsatellite polymorphisms. The level of sensitivity of
this method is approximately 1% residual recipient cells. All (N:
74) children transplanted for leukaemia or MDS between 97.10.20
and 05.09.01 were examined consecutively for the presence of MC.
An initial analysis of the MC courses revealed three main patterns:
1) Early MC (d90), 2) Late MC (d90) and 3) MC as an
integrated part of an ongoing histiological veriﬁed relapse. We
have evaluated associations between early as well as late MC and
the occurence of later relapse.
Furthermore, MC was examined in patients transplanted for
non-malignant disease (N: 25). Only patients who had at least
one examination showing MC and who had measurements of
MC at least one year post SCT were included in this evaluation.
MC were examined on 11 occations (mean, range: 3-29). The
last examination was 3.1 years (mean, range: 1.2-5.8) after trans-
plant.
Results. Among leukaemia patients (N: 24) who later relapsed
34% showed signs of early MC whereas, 35% of leukaemia patients
(N: 50) who did not relapse showed signs of early chimerism. Late
MC was observed in 25% of patients who relapsed and among 22%
of patients who did not relapse. Similarly, when ALL patients were
examined separately (N: 47) no signiﬁcant difference in MC (early
or late) was recorded between patients who later relapsed and those
who didnt.
Patients with MC transplanted for non-malignant diseases in
average showed constant MC levels 0.49 years (mean, range: 0.05-
1.83) after transplant.
Conclusion. 1) In paediatric patients with leukaemia the pres-
ence of MC is not associated with recurrence if the MC is not an
integrated part of a histiological relapse. 2) In patients with early
MC, one half of these achieve a stable level of chimerism within
the ﬁrst 0.5 year and maintaine this level thereafter. Signiﬁcant
changes are rare after 1.8 years post transplant.
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IMPACT OF 100-DAY SURVIVAL ON LONG-TERM OUTCOME OF MY-
ELOABLATIVE TRANSPLANT AT AN EARLY STAGE OF LEUKEMIA
Hiraoka, A.1 1Osaka Medical Center for Cancer and CVD, Osaka,
Japan.
Objective; There is a growing demand for quality improvement
in hemtopoietic stem cell transplantation (HSCT) as in other ﬁelds
of patient management. An indicator(s) is necessary for the quality
assurance, which ﬁnally leads a continuous quality improvement
process. We analyzed the impact of survival rate at 100 days
post-transplant (100-day S)on the long-term outcome in leukemia
patients who received a myeloablative HSCT at an early stage of
leukemia.
Methods; Two databases were used; one from our hospital (1),
and one from Japan Marrow Donor Program Registry (JMDPR)
(2). (1) Total 229 patients who received a transplant at 1st CP of
CML or 1st or 2nd CR of acute leukemia at our hospital were
divided into two groups; 65 patients who received a related
transplant before 1988 or unrelated transplant before 1997
(group E) and the remaining 164 patients (group L). (2) Total
1,203 patients received an unrelated transplant via JMDPR at 1st
CP or 1st CR from 1993 to 2001. Number of hospital which
performed at least 10 transplants was 40. Among these 40
hospitals, 6 hospitals showed a signiﬁcantly lower 100-day S
than the average of all of 1,203 patients. Total 125 patients
received a transplant at these 6 hospitals (group B) and total 697
patients at the remaining 34 hospitals (group G).
Results; (1) The 100-day S was 83.1% in group E and 95.7% in
group L (p0.001). Overall survival (OS) at 5 years was 62.5% in
group E and 74.6% in group L (p0.049). OS at 5 years of
survivors over 100 days post-transplant was 74.1% in group E and
78.4% in group L (p0.54). (2) The 100-day S was 66.4% in group
B and 89.6% in group G (p0.001). OS at 10 years was 47.0% in
group B and 59.7% in group G (p0.001). OS at 10 years of
survivors over 100 days post-transplant was 70.8% in group B and
66.3% in group G (p0.68).
Conclusions; In these two patient populations, patient groups
with a lower 100-day S showed a worse long-term outcome. Sur-
vivors over 100 days post-transplant in both patient groups showed
a similar long-term outcome. Thus the 100-day S might be an
indicator for the quality assurance of myeloablative HSCT at an
early stage of leukemia.
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